New insider activity at AbbVie ( (ABBV) ) has taken place on March 6, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SVP and Controller David Ryan Purdue has sold 5,230 shares of AbbVie stock in a transaction valued at $1,221,518, signaling a notable insider move at the pharmaceutical company.
Recent Updates on ABBV stock
AbbVie shares reflected a mix of balance‑sheet and pipeline signals over the last day, as investors weighed an $8B multi‑tranche notes offering that raises long‑term funding but underscores leverage concerns alongside a rich P/E. At the same time, multiple clinical updates across venetoclax, SKYRIZI, XEN45, and upadacitinib reinforced the company’s growth and diversification story, supporting constructive technicals and a strong earnings outlook that inform analyst reassessments of valuation rather than near‑term trading moves.
Spark’s Take on ABBV Stock
According to Spark, TipRanks’ AI Analyst, ABBV is a Neutral.
The score is driven primarily by mixed fundamentals: strong cash generation and improving revenue trajectory are offset by high leverage/negative equity and weaker net profitability. Positive earnings-call guidance (higher 2026 growth, margin expansion, and large free cash flow) and constructive technical momentum support the outlook, but an elevated P/E keeps the overall score in the low-to-mid 60s.
To see Spark’s full report on ABBV stock, click here.
More about AbbVie
YTD Price Performance: 2.51%
Average Trading Volume: 6,696,137
Technical Sentiment Signal: Buy
Current Market Cap: $410.8B